Neurocrine names Eiry Roberts chief medical officer, replacing Sanjay Keswani
The Board made the change effective September 28, 2026, after Keswani's departure was agreed on September 25.
SEC filing
Latest
5 stories
Yesterday
Monday, September 28
Tuesday, September 22
Neurocrine registers Phase 2a trial of NBI-1117567 in mild to moderate Alzheimer's disease
Thursday, August 6
Voyager reports Q2 2026 results, sets Q4 milestones for two Alzheimer's programs
The company said tau PET imaging data for VY7523 and dosing initiation for VY1706 are both expected in the fourth quarter of 2026, with cash runway now guided into 2028.
SEC filing
Thursday, July 30
Neurocrine reports Q2 2026 results, raises INGREZZA guidance, cites 2027 pipeline readouts
The company pointed to 2027 Phase 3 data for osavampator and direclidine while reporting new CAHtalyst and VYKAT XR results and a completed Soleno acquisition.
SEC filing